No Data
LAVA Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 222.58% HC Wainwright & Co. $6 → $6 Reiterates Buy → Buy 03/21/2024 222.58% HC Wainwright & Co.
H.C. Wainwright Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright analyst Arthur He CFA maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 47.8%
Little Excitement Around LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues As Shares Take 26% Pounding
Unfortunately for some shareholders, the LAVA Therapeutics N.V. (NASDAQ:LVTX) share price has dived 26% in the last thirty days, prolonging recent pain. The recent drop has obliterated the annual r
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)
JMP Securities Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
JMP Securities analyst Reni Benjamin maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 35.5%
Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)